drugset / Trial / NCT07072195
A Study of AMC6156 in People With Sarcopenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-03
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMC6156 | Unknown | 0.1 mg | Oral |
| Subject | AMC6156 | Unknown | 0.3 mg | Oral |
| Subject | AMC6156 | Unknown | 1 mg | Oral |